Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159573 · ClinicalTrials.gov registry record
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 530
- Enrollment target
NCT02159573: Completed study, sponsored by Biogen.
NCT02159573 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 530 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02159573 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 530 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate relapse activity, as measured by the proportion of participants relapsed at 12 months, in participants with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (BG00002) to Tecfidera (BG00012) in the real-world setting. The secondary objective is to further evaluate relapse activity, defined as annualized relapse rate (ARR), hospitalization and intravenous corticosteroid use, during the first year of Tecfidera treatment following transition from Tysabri treatment.
Interventions
- DRUG dimethyl fumarate
- BIOLOGICAL natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-01 |
What the finished NCT02159573 record still lists
NCT02159573 is an observational study that tracks outcomes without assigning an intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which dimethyl fumarate is the first listed.
NCT02159573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02159573 about?
NCT02159573 is a clinical study titled "Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)". The primary objective of the study is to evaluate relapse activity, as measured by the proportion of participants relapsed at 12 months, in participants with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (BG00002) to Tecfidera (BG00012) in the real-world setting. The seco...
What is the current status of trial NCT02159573?
This trial is currently completed. The enrollment target is 530 participants. The study started on 2014-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02159573?
The interventions under investigation include: dimethyl fumarate (DRUG), natalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02159573?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia